Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)

This article has no abstract
Epistemonikos ID: ed6ca79e774d8e85c5d45918016f8c57203764d9
First added on: Feb 05, 2025